Fatty Liver
Conditions
Brief summary
fatty liver disease is characterized by low antioxidants, disturbed lipid metabolism, cardioautonomic functions, and elevated blood measures (glucose, inflammatory markers, liver enzymes)
Detailed description
In fatty liver patients,applied cupping (with scarification) will be compared, regarding its effect on antioxidant, lipid metabolism, cardioautonomic functions, and blood measures (glucose, inflammatory markers, liver enzymes), to application of laser on acupoints
Interventions
DEVICElaser acupuncture
In fatty liver diseased patients which their number will be 30 patients, a 3-session/week application of 2-minute laser (for 3 months) on acupoint number 25,40,36 of stomach meridian, acupoints number 3 and 14 of liver meridian, acupoint number 6 of spleen meridian,acupoint number 9.12,4 of conception vessel meridian, acupoint number 14 of governor vessel meridian, acupoint number 4, 11 of large intestine meridian, acupoint number 34 of gall bladder meridian
OTHERwet cupping
in this fatty liver diseased patients which their number will be 30, cupping (with scarification) or wet cupping will be applied at the first day and the day number 14 in the month for three successive months. cupping (with scarification) or wet cupping will be applied on urinary bladder acupoint 17 (on the both sides) and governosal vessels acupoints 12,13,and 14.
Sponsors
Cairo University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
35 Years to 55 Years
Healthy volunteers
No
Inclusion criteria
* fatty liver obese patients
Exclusion criteria
thoracic diseases heart diseases kidney diseases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| high density lipoprotein | 12 weeks | it is a component of lipid profile |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| low density lipoprotein | 12 weeks | it is a component of lipid profile |
| triglycerides | 12 weeks | it is a component of lipid profile |
| blood glucose | 12 weeks | fasting level of blood glucose will be measured |
| C reactive protein | 12 weeks | high sensitivity levels C reactive protein will be measured |
| Malondialdehyde | 12 weeks | it ts oxidative stress marker |
| cholesterol | 12 weeks | it is a component of lipid profile |
| alanine transaminase | 12 weeks | it is a hepatic enzyme that reports the functions of liver |
| systolic blood pressure | 12 weeks | it will be measured by sphygmomanometer |
| diastolic blood pressure | 12 weeks | it will be measured by sphygmomanometer |
| pulse rate | 12 weeks | it will be measured manually |
| aspartate transaminase | 12 weeks | it is a hepatic enzyme that reports the functions of liver |
Countries
Egypt
Contacts
Primary ContactAli Ismail, lecturer
Backup Contactahmed Elfahl, Lecturer
Outcome results
None listed